ChromaCure’s mission is to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company is developing inhibitors of a novel target that is a key regulator of tumor initiation and progression, based on research conducted at the Laboratory of Stem Cells and Cancer of the Blanpain Laboratory, at the Université libre de Bruxelles (ULB).
Cédric Blanpain graduated as a Medical Doctor, and is board certified in internal medicine, from the Université libre de Bruxelles, Belgium (ULB).
He conducted his PhD work in Prof. Marc Parmentier’s lab and his postdoc with Prof. Elaine Fuchs, Rockefeller University, USA.
Cédric started his lab as assistant professor (chercheur qualifié) of the Belgian National Science Research Fund (FNRS) at the Interdisciplinary Research Institute (IRIBHM) of ULB.
He is now full professor, Director of the Laboratory of Stem Cells and Cancer and WELBIO investigator. Cédric Blanpain has authored and published more than a hundred highly-cited papers in leading scientific journals, including Nature, Cell and Science.
He received prestigious and highly competitive awards including the EMBO Young investigator award, ERC starting and ERC consolidator grants, the outstanding young investigator award of the International Society of Stem Cell Research, the Liliane Bettencourt award for life sciences and the Joseph Maisin Award.
In 2012, Cédric Blanpain was selected by Nature as one of “The ten scientists that matter”.
He is a member of EMBO, the Belgian Royal Academy of Medicine, and Academia Europaea.
Jalal Vakili, CEO, who has been involved in various aspects of drug development, with a focus on oncology, for the past 15 years. After completing his medical training and obtaining his PhD in Biomedical Sciences at ULB, Jalal went on to complete his post-doctoral work at Immunex Corporation in Seattle. He then worked in different start-ups in the Seattle area, before returning to Belgium in 2010 and joining Ablynx as a senior scientist. He joined the Jules Bordet Cancer Centre in Brussels in 2012 as director of research operations. Before joining ChromaCure, Jalal was Director of External Opportunities in the Oncology Centre for Innovation of the French pharmaceutical group Servier.
Marie Miglianico obtained her PhD degree at Maastricht University (NL) on a drug discovery project in the field of metabolic disorders. She later joined a startup company based in Nijmegen (NL) where she was responsible for several drug screening projects on malaria parasites and vectors. Marie started in November 2018 and is using her drug development expertise to contribute to discovery and assay development at Chromacure
Marylene Poelaert holds a Master in history and a Master in information science. She has been chief of staff for the President (Rector) of the Université Libre de Bruxelles for more than seven years. Marylène joined ChromaCure in December 2018.
Please complete the form below.